How GLP-1 drugs compare in heart health for adults with type 2 diabetes and moderate heart risk

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: In the last 36 months, JH received support from the Centers for Medicare and Medicaid Services, NIH, Agency for Healthcare Research and Quality, PCORI, and the American Heart Association. JJN is supported by a NIH research grant and a foundation grant from the American College of Clinical Pharmacy, serves as a consultant to Bayer, Eli Lilly, Boehringer Ingelheim, and Proteomics International, and receives support from the American Diabetes Association for projects unrelated to this work. RJG is supported by grants from NIDDK of NIH. RJG received research support from Novo Nordisk, Boehringer, Eli Lilly, and Dexcom, and consulting/advisory from Abbott Diabetes, Astra-Zeneca, Bayer, Boehringer, Dexcom, Eli Lilly, and Novo Nordisk, and Medtronic. GEU is supported by research grants from NIH and National Center for Research Resources and has received research support (to Emory University) from Abbott, Dexcom, Corcept, and Bayer, and served as a member of advisory boards for Dexcom, Glucotrack and GlyCare. JSR receives research support through Yale University from Johnson and Johnson to develop methods of clinical trial data sharing, from FDA for the Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation program (U01FD005938), from the Agency for Healthcare Research and Quality (R01HS022882), and from Arnold Ventures; formerly received research support from the Medical Device Innovation Consortium as part of the National Evaluation System for Health Technology; and was an expert witness at the request of Relator's attorneys, the Greene Law Firm, in a qui tam suit alleging violations of the False Claims Act and Anti-Kickback Statute against Biogen Inc. that was settled September 2022. BJB serves as a consultant to Boehringer-Ingelheim on projects unrelated to this study. RGM has received support from the NIDDK of NIH, the National Institute on Aging of the NIH, the National Center for Advancing Translational Sciences, and the American Diabetes Association for projects unrelated to this work. She also served as a consultant to EmmiEducate® (Wolters Kluwer) and the Yale-New Haven Health System and received speaking honoraria and travel support from the American Diabetes Association.